"...the pharmaceutical R&D sector can do more to work together" said Remnant, noting that it would be desirable for companies to pool their resources in non-competitive areas of R&D to cut cost, remove duplication of work and make the operations of service provider more efficient. "Sharing knowledge on the science behind failed molecules and studies will help improve success rates, and ultimately bring down the cost to develop new medicines" Julian Remnant/Deloitte
Ver
Ver también:
Pharma needs to collaborate to boost R&D return
Entradas
No hay comentarios:
Publicar un comentario